Our results showed that the PSMD9 overexpression-induced promotion of cell proliferation, migration and invasion could be attenuated by erlotinib in HCC cells (Fig. 7H-K, supplementary Figure S6D-S6E). Here, PSMD9 is linked to hepatocellular carcinoma.